BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 25746843)

  • 1. Model of mucociliary clearance in cystic fibrosis lungs.
    Kurbatova P; Bessonov N; Volpert V; Tiddens HA; Cornu C; Nony P; Caudri D;
    J Theor Biol; 2015 May; 372():81-8. PubMed ID: 25746843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to section I: overview of approaches to study cystic fibrosis pathophysiology.
    Clunes MT; Boucher RC
    Methods Mol Biol; 2011; 742():3-14. PubMed ID: 21547723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic fibrosis: a disease of vulnerability to airway surface dehydration.
    Boucher RC
    Trends Mol Med; 2007 Jun; 13(6):231-40. PubMed ID: 17524805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Airway mucus in cystic fibrosis.
    Puchelle E; Bajolet O; Abély M
    Paediatr Respir Rev; 2002 Jun; 3(2):115-9. PubMed ID: 12297057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
    Tiddens HA; Donaldson SH; Rosenfeld M; Paré PD
    Pediatr Pulmonol; 2010 Feb; 45(2):107-17. PubMed ID: 20082341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis.
    Hoegger MJ; Fischer AJ; McMenimen JD; Ostedgaard LS; Tucker AJ; Awadalla MA; Moninger TO; Michalski AS; Hoffman EA; Zabner J; Stoltz DA; Welsh MJ
    Science; 2014 Aug; 345(6198):818-22. PubMed ID: 25124441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH.
    Hill DB; Long RF; Kissner WJ; Atieh E; Garbarine IC; Markovetz MR; Fontana NC; Christy M; Habibpour M; Tarran R; Forest MG; Boucher RC; Button B
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in understanding mucus abnormalities in cystic fibrosis airways.
    Wine JJ; Hansson GC; König P; Joo NS; Ermund A; Pieper M
    J Cyst Fibros; 2018 Mar; 17(2S):S35-S39. PubMed ID: 28951068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options for hydrating airway mucus in cystic fibrosis.
    Tildy BE; Rogers DF
    Pharmacology; 2015; 95(3-4):117-32. PubMed ID: 25823699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.
    Danahay HL; Lilley S; Fox R; Charlton H; Sabater J; Button B; McCarthy C; Collingwood SP; Gosling M
    Am J Respir Crit Care Med; 2020 Apr; 201(8):946-954. PubMed ID: 31898911
    [No Abstract]   [Full Text] [Related]  

  • 12. Cystic fibrosis and other respiratory diseases of impaired mucus clearance.
    Livraghi A; Randell SH
    Toxicol Pathol; 2007 Jan; 35(1):116-29. PubMed ID: 17325980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an airway mucus defect in the cystic fibrosis rat.
    Birket SE; Davis JM; Fernandez CM; Tuggle KL; Oden AM; Chu KK; Tearney GJ; Fanucchi MV; Sorscher EJ; Rowe SM
    JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Numerical and experimental investigation of mucociliary clearance breakdown in cystic fibrosis.
    Chatelin R; Anne-Archard D; Murris-Espin M; Thiriet M; Poncet P
    J Biomech; 2017 Feb; 53():56-63. PubMed ID: 28117099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for hypertonic saline therapy for cystic fibrosis lung disease.
    Tarran R; Donaldson S; Boucher RC
    Semin Respir Crit Care Med; 2007 Jun; 28(3):295-302. PubMed ID: 17562499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CFTR in airway disease.
    Pilewski JM; Frizzell RA
    Physiol Rev; 1999 Jan; 79(1 Suppl):S215-55. PubMed ID: 9922383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets.
    Haq IJ; Gray MA; Garnett JP; Ward C; Brodlie M
    Thorax; 2016 Mar; 71(3):284-7. PubMed ID: 26719229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy.
    Boucher RC
    Annu Rev Med; 2007; 58():157-70. PubMed ID: 17217330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches.
    Puchelle E; de Bentzmann S; Zahm JM
    Respiration; 1995; 62 Suppl 1():2-12. PubMed ID: 7792436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.
    Fernandez-Petty CM; Hughes GW; Bowers HL; Watson JD; Rosen BH; Townsend SM; Santos C; Ridley CE; Chu KK; Birket SE; Li Y; Leung HM; Mazur M; Garcia BA; Evans TIA; Libby EF; Hathorne H; Hanes J; Tearney GJ; Clancy JP; Engelhardt JF; Swords WE; Thornton DJ; Wiesmann WP; Baker SM; Rowe SM
    JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.